Company news
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news
Inovio Pharmaceuticals, Inc. news releases on 6ix. Latest, Aug 8, 2024: INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Press releases — page 2
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 7, 2024
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
July 24, 2024
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
July 24, 2024
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway
July 10, 2024
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
July 1, 2024
INOVIO Added to Russell 2000® Index Effective July 1, 2024
June 30, 2024
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
June 3, 2024
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 12, 2024
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
April 28, 2024
INOVIO to Participate in Upcoming Investor Conferences in May
April 28, 2024
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
April 14, 2024
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
March 25, 2024
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
March 5, 2024
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 5, 2024
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
February 20, 2024
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 6, 2024
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
January 22, 2024
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
January 21, 2024
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
January 3, 2024
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
January 2, 2024
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
November 8, 2023
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
October 25, 2023
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
October 9, 2023
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
September 6, 2023
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
August 8, 2023
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
July 25, 2023
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
June 22, 2023
INOVIO to Present at the 2023 Jefferies Healthcare Conference
May 24, 2023
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
May 22, 2023
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
May 9, 2023
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
May 7, 2023
INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 4, 2023
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
April 27, 2023
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
April 26, 2023
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023
April 11, 2023
INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights
February 28, 2023
INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
February 15, 2023
INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023
February 14, 2023
INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
February 1, 2023
INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates
January 30, 2023
INOVIO Provides an Update on Lassa Fever and MERS Programs
November 16, 2022
INOVIO Reports Financial Results and Highlights for the Third Quarter 2022
November 7, 2022
INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
October 26, 2022
INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022
October 24, 2022
INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
October 12, 2022
INOVIO Reports Financial Results and Highlights for the Second Quarter 2022
August 8, 2022
INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022
July 25, 2022
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients
July 18, 2022
INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 30, 2022